Wednesday, December 8th |
| Time | Event |
| 9:00am - 9:25am | Welcome Remarks/Keynote Introduction |
| 9:30am - 10:15am | Keynote Presentation: SBS and 20 years of Drug Screening Jeff Paslay, Pfizer, USA |
| Drug Screening Chair: Steve Rees, GlaxoSmithKline, UK | Drug Discovery Technologies Chairs: Zhong Zhong, GlaxoSmithKline R " D, China Kelvin Lam, Harvard Stem Cell Institute, Harvard University, USA> |
| 10:15am - 10:45am | Plenary Presentation: Overview of Drug Discovery Process John Mathias, Pfizer, UK | Plenary Presentation:> Extreme Makeover: Emerging Trends in Cell Based Assays> Richard Eglen, PerkinElmer, USA |
| 10:45am - 11:15am | Refreshment Break |
| 11:15am - 11:45am | Assay Development for High Throughput Screening and Compound Profiling Steve Rees, GlaxoSmithKline, UK | Critical Factors to Make Cryopreserved Assay-Ready Cells for HTS Mei Cong, Promega, USA |
| 11:45am - 12:15pm | Generation and Maintenance of a High Quality Compound Collection Robert Lifely, GlaxoSmithKline, USA | Stem Cells in Drug Screening Sitta Sittampalam, University of Kansas Medical Center, USA |
| 12:15pm - 1:45pm | Lunch in Exhibit Hall |
| 1:45pm - 2:30pm | Tutorials |
| 2:30pm - 2:35pm | Introduction of Keynote Speaker |
| 2:35pm - 3:20pm | Keynote Presentation Drug Discovery and Medicinal Chemistry: Rules and Filters and Their Sensible Use Christopher A. Lipinski, Ph.D., Melior Discovery |
| 3:20pm - 3:50pm | Plenary Presentation:> HTS in NIH Wei Zhang, National Institutes of Health, USA | Plenary Presentation:> Nuclear Receptor Drug Discovery Taosheng Chen, St. Jude Children’s Research Hospital, USA |
| 3:50pm - 4:20pm | Refreshment Break |
| 4:20pm - 4:50pm | Presentation to be announced | Ion Channel Drug Discovery Michael Xie, GlaxoSmithKline |
| 4:50pm - 5:20pm | Presentation to be announced | Label-Free Lance Liang, SRU Biosystems, USA |
Thursday, December 9th
| Time | Event |
| 9:00am - 9:20am | Welcome Remarks/Keynote Introduction |
| 9:20am - 10:05am | Keynote Presentation: Revolution and Harmony for Pharmaceutical R"D in Academia and Pharma Melvin Reichman, Lankenau Institute for Medical Research, USA |
| Target Based Drug Discovery Chair: En Li, Novartis | Regional Topics Chair: Zhong Zhong, GlaxoSmithKline R " D, China> |
| 10:05am - 10:35am | Plenary Presentation:> Structure-Based Drug Discovery for GPCRs Christopher Langmead, Heptares Therapeutics, UK | Plenary Presentation: Drug Discovery Need in Asia Steve Yang, Pfizer |
| 10:35am - 11:05am | Refreshment Break |
| 11:05am - 11:35am | Discovery of GPCR Heteromer-Biased Pharmacology> Kevin Pfleger, University of Western Australia, Australia | Presentation to be announced |
| 11:40am - 12:10pm | Agonist Trafficking of Signals and Arrestin Activation. Do Biased Ligands Offer Therapeutic Potential? Graeme Milligan, University of Glasgow, UK | Drug Discovery/Development by Domestic Company Seymour Mong, Jiangsu Hengrui Medicine Company, China |
| 12:15pm - 1:45pm | Lunch in Exhibit Hall |
| 1:45pm - 2:30pm | Tutorials |
| 2:30pm - 2:35pm | Introduction of Keynote Speaker |
| 2:35pm - 3:20pm | Keynote Presentation Drug Discovery in China Kiaxian Chen, Shanghai Institute of Materia Medica |
| 3:20pm - 3:50pm | Kinase Drug Discovery Bill Janzen, University of North Carolina at Chapel Hill, USA | Integrate CRO into R"D Ge Li, Ph.D., WuXi AppTec, China |
| 3:50pm - 4:20pm | Refreshment Break |
| 4:20pm - 4:50pm | Enhancing Hit Finding, Hit Validation and Lead Optimization by Modern Compound Profiling Lorenz Mayr, Novartis Pharma AG, Switzerland | Lead Discovery in China En Li, Ph.D., Novartis, China |
| 4:50pm - 5:20pm | Epigenetics and CancerRobert Campbell, Eli Lilly and Company, Singapore | Presentation to be announced |
